AP9901582A0 - Combination therapy for musculoskeletal frailty. - Google Patents

Combination therapy for musculoskeletal frailty.

Info

Publication number
AP9901582A0
AP9901582A0 APAP/P/1999/001582A AP9901582A AP9901582A0 AP 9901582 A0 AP9901582 A0 AP 9901582A0 AP 9901582 A AP9901582 A AP 9901582A AP 9901582 A0 AP9901582 A0 AP 9901582A0
Authority
AP
ARIPO
Prior art keywords
compositions
frailty
combination therapy
oxo
phenyl
Prior art date
Application number
APAP/P/1999/001582A
Inventor
Huazhu Ke
Mei Li
Lydia Codetta Pan
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP9901582A0 publication Critical patent/AP9901582A0/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This invention is directed to pharmaceutical combination compositions and methods containing (-)-cis-6-phenyl-5-(4-(2-pyrrolidin-1-yl-ethoxy)-phenyl)-5,6,7,8-tetrahydronaphthalene-2-ol or a pharmaceutically acceptable salt thereof and 2-amino-n-(2-(3a(r)-benzyl-2-methyl-3-oxo-2,3, 3a, 4,6,7-hexahydor-pyrazolo-[4,3-c]pyridin-5-yl)-1(r)-benzyloxymethyl-2-oxo-ethyl)-isobutyramide or a pharmaceutically acceptable salt thereof, methods of using such compositions and kits containing such compositions. The compositions are useful for treating musculoskeletal frailty, including osteoporosis, osteoporotic fracture, low bone mass, frailty and low muscle mass.
APAP/P/1999/001582A 1998-06-16 1999-06-15 Combination therapy for musculoskeletal frailty. AP9901582A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8946998P 1998-06-16 1998-06-16

Publications (1)

Publication Number Publication Date
AP9901582A0 true AP9901582A0 (en) 1999-06-30

Family

ID=22217825

Family Applications (1)

Application Number Title Priority Date Filing Date
APAP/P/1999/001582A AP9901582A0 (en) 1998-06-16 1999-06-15 Combination therapy for musculoskeletal frailty.

Country Status (30)

Country Link
EP (1) EP1087764A1 (en)
JP (1) JP2002518326A (en)
KR (1) KR20010052852A (en)
CN (1) CN1301160A (en)
AP (1) AP9901582A0 (en)
AR (1) AR018869A1 (en)
AU (1) AU4054799A (en)
BG (1) BG105041A (en)
BR (1) BR9911324A (en)
CA (1) CA2335134A1 (en)
CO (1) CO5070587A1 (en)
EA (1) EA200001186A1 (en)
GT (1) GT199900087A (en)
HN (1) HN1999000097A (en)
HR (1) HRP20000859A2 (en)
HU (1) HUP0102505A3 (en)
ID (1) ID27599A (en)
IL (1) IL138630A0 (en)
IS (1) IS5691A (en)
MA (1) MA26652A1 (en)
NO (1) NO20006312L (en)
OA (1) OA11505A (en)
PA (1) PA8475901A1 (en)
PE (1) PE20000646A1 (en)
PL (1) PL344981A1 (en)
SK (1) SK18912000A3 (en)
TN (1) TNSN99124A1 (en)
TR (1) TR200003544T2 (en)
WO (1) WO1999065486A1 (en)
ZA (1) ZA993975B (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2360103A1 (en) * 1999-02-08 2000-08-17 Robert Sladek Non-human transgenic animal whose germ cells and somatic cells contain a knockout mutation in dna encoding orphan nuclear receptor erralpha
ATE346159T1 (en) 2000-05-08 2006-12-15 Pfizer Prod Inc ENZYMATIC CLEAVAGE OF SELECTIVE MODULATORS OF THE ESTROGEN RECEPTOR
IL145106A0 (en) * 2000-08-30 2002-06-30 Pfizer Prod Inc Intermittent administration of a geowth hormone secretagogue
BR0113626A (en) 2000-08-30 2003-06-17 Pfizer Prod Inc Sustained-Release Formulations for Growth Hormone Secretors
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
WO2006024931A2 (en) * 2004-08-31 2006-03-09 Pfizer Products Inc. Therapeutic combinations comprising a selective estrogen receptor modulator and a selective androgen receptor modulator
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
EA200901077A1 (en) 2007-02-09 2010-04-30 Транзим Фарма, Инк. MACRO CYCLIC MODULATORS OF THE GREEL RECEPTOR AND THEIR APPLICATION

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA51676C2 (en) * 1995-11-02 2002-12-16 Пфайзер Інк. (-)cis-6(S)-phenyl-5(R)-[4-(2-pyrrolidin-I-ylethoxy)phenyl]-5,6,7,8-tetrahydronaphthalen-2-ol D-tartrate, a method of its preparation, method of THE treatment OF diseases medicated by agonists of estrogen and a pharmaceutical composition
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS

Also Published As

Publication number Publication date
AU4054799A (en) 2000-01-05
HRP20000859A2 (en) 2001-04-30
HUP0102505A3 (en) 2002-12-28
EP1087764A1 (en) 2001-04-04
MA26652A1 (en) 2004-12-20
CN1301160A (en) 2001-06-27
BG105041A (en) 2001-08-31
PE20000646A1 (en) 2000-08-05
CO5070587A1 (en) 2001-08-28
TNSN99124A1 (en) 2005-11-10
SK18912000A3 (en) 2001-10-08
BR9911324A (en) 2001-04-03
CA2335134A1 (en) 1999-12-23
HUP0102505A2 (en) 2001-11-28
IL138630A0 (en) 2001-10-31
AR018869A1 (en) 2001-12-12
EA200001186A1 (en) 2001-06-25
NO20006312D0 (en) 2000-12-12
ZA993975B (en) 2000-12-15
OA11505A (en) 2004-05-07
GT199900087A (en) 2000-12-07
IS5691A (en) 2000-10-27
WO1999065486A1 (en) 1999-12-23
HN1999000097A (en) 1999-11-03
JP2002518326A (en) 2002-06-25
KR20010052852A (en) 2001-06-25
TR200003544T2 (en) 2001-04-20
PL344981A1 (en) 2001-11-19
NO20006312L (en) 2000-12-12
PA8475901A1 (en) 2000-05-24
ID27599A (en) 2001-04-12

Similar Documents

Publication Publication Date Title
DE60037836D1 (en) ThiazoloÄ4,5-diphyrimidine compounds for the treatment of rheumatoid arthritis
NO990663D0 (en) Substituted pyrimidine derivatives and their pharmaceutical use
LU91145I2 (en) FIROCOXIB optionally in the form of a pharmaceutically acceptable salt (PREVICOX).
UA84146C2 (en) Amides of pyrrolopyridine-2-carboxylic acid as inhibitors of glycogen phosphorylase, method for their synthesis, drug formulation, and their use as therapeutic agents
AP9901582A0 (en) Combination therapy for musculoskeletal frailty.
NO20001515L (en) Vitronectin receptor antagonist
SE0101322D0 (en) Novel compounds
AP9901580A0 (en) Therapeutic combination comprising a selective estrogen receptor modulator and parathyroid hormone.
AP9901581A0 (en) Therapeutic combinations for musculoskeletal frailty.
ECSP993020A (en) COMBINATION THERAPY FOR MUSCULOSKELETAL FRAGILITY
ECSP993021A (en) THERAPEUTIC COMBINATIONS FOR MUSCULOSKELETAL FRAGILITY
CA2274381A1 (en) Therapeutic combinations comprising a selective estrogen receptor modulator and prostaglandin e2
UA40196A (en) Method for surgical treatment of dislocation-fracture of proximal end of humerus